에 대한 최신 뉴스 UnitedHealth Group (NYSE:UNH) 주식

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Broad U.S. Equity ETFs

Trading Ideas

ETFs

SPDR Dow Jones Industrial Average ETF Trust

INTC

NVDA

기술 대기업인 엔비디아(NASDAQ:NVDA)가 다우존스 산업평균지수에 11월 8일 인텔(NASDAQ:INTC)을 대체하여 합류할 예정이다. 이는 여러 시장 전문가들에 의해 몇 달 전 벤징가에 의해 예측된 바 있다.

엔비디아가 다우존스 지수에 합류: 지수에서 어떤 순위? 셔윈 윌리엄즈의 추가도 주목

News

Markets

General

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.

콜럼버스 데이: 오늘 주식시장이 열리나요?

Government

Long Ideas

Regulations

Health Care

미국 연방거래위원회(FTC)가 유나이티드헬스 그룹(NYSE:UNH), CVS 헬스(NYSE:CVS) 및 시그나 그룹(NYSE:CI)의 처방약급여관리업체(PBM)들을 철저히 조사하고 있는 가운데, 투자자들은 어떤 의료 대기업이 이 위기를 가장 잘 이겨낼 수 있을지 궁금해하고 있다. 인슐린 가격을 부풀린 혐의로 이들 회사를 대상으로 한 이번 FTC의 소송은 의료 산업 전반에 큰 파급 효과를 미칠 수 있으며 이는 주식 변동성을 의미한다.

유나이티드헬스 vs CVS 헬스 vs 시그나: FTC 조사 및 규제 위기를 잘 이겨낼 의료 주식은?

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

WIIM

Shares of health insurance stocks are trading higher in possible reaction to President-elect Donald Trump indicating he plans to nominate Dr. Mehmet Oz as administrator for the Centers for Medicare and Medicaid Services. Oz has reportedly supported Medicare Advantage plans.

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Large Cap

Legal

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

<a href="https://news.bloomberglaw.com/antitrust/cvs-cigna-unitedhealth-sue-to-block-ftc-case-on-insulin-costs">https://news.bloomberglaw.com/antitrust/cvs-cigna-unitedhealth-sue-to-block-ftc-case-on-insulin-costs</a>
&nbsp;

Reported November 19, 2024 "CVS, Cigna, UnitedHealth Sue To Nix FTC Case On Insulin Cost" - Bloomberg Law

President-elect Donald Trump on Tuesday said he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Medicare and Medicaid Services (CMS). </a>
The Details: Trump announced Dr. Oz as his pick for CMS administrator in a statement Tuesday afternoon.&nbsp;
"Our broken Healthcare System harms everyday Americans, and crushes our country's budget," Trump said.&nbsp;
"Dr. Oz will be a leader in incentivizing disease prevention, so we get the best results in the world for every dollar we spend on health care in our Great Country," Trump said. "He will also cut waste and fraud within our country's most expensive government agency, which is a third of our nation's health care spend, and a quarter of our entire national budget."
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
Dr. Oz has a history of offering unproven medical advice and has said his goal was to "empower" Americans to take control of their health, according to the New York Times. He <a href="https://www.nytimes.com/2021/12/26/us/politics/dr-oz-medical-advice.html">promoted the use</a> of hydroxychloroquine as an effective treatment against COVID-19 in the early days of the pandemic, before reversing course and advising patients to wait for evidence from randomized trials.&nbsp;
CMS, an agency within the Health and Human Services Department (HHS), oversees several major health care programs including Medicare, Medicaid, the Children's Health Insurance Program and the Healthcare.gov insurance marketplace exchange. Federal spending on the four programs is $1.6 trillion, or nearly 25% of the entire federal budget.
Last week, Trump announced his intention to nominate another <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">controversial figure,</a> Robert Kennedy Jr., to head the HHS.&nbsp; Other unconventional selections include Trump's choices of former Rep. Matt Gaetz for U.S. attorney general and Fox News host Pete Hegseth for defense secretary.
Chiquita Brooks-LaSure is the current CMS administrator under the Biden administration.&nbsp;
Following Trump&#8217;s announcement, investors may want to monitor shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer nationwide, and shares of Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid insurers.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: G. Holland via Shutterstock

Politics

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares have declined 5.3% over the past week as the company faces a significant legal challenge to its <a href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on">$3.3 billion acquisition</a> of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
What To Know: The U.S. Justice Department, along with attorneys general from multiple states, has recently filed a lawsuit to block the deal, citing antitrust concerns in the home health services sector. 
The agency argues the merger could lead to higher healthcare costs, particularly as Amedisys is a direct competitor to UnitedHealth&#8217;s LHC Group, which was acquired for $5.4 billion in 2022.
The Justice Department contends that allowing the merger would tighten UnitedHealth&#8217;s control over the home health and hospice care market, potentially disadvantaging seniors and caregivers. 
In response, UnitedHealth and Amedisys have proposed selling assets to VitalCaring Group to address these concerns, but negotiations have yet to alleviate regulatory resistance.
UnitedHealth's Optum unit has actively <a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape">defended the merger</a>, emphasizing the fragmented nature of the home healthcare industry and its potential to address the growing demand for elder care as the U.S. population ages. However, skepticism persists as analysts and regulators scrutinize the impact on market competition.
Read Also: <a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a>
<h2 class="wp-block-heading">How To Buy UNH Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in UnitedHealth Group&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, UNH has a 52-week high of $630.73 and a 52-week low of $436.38.

AMED

What's Going On With UnitedHealth Stock?

High-rolling investors have positioned themselves bearish on UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in UNH often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 20 options trades for UnitedHealth Group. This is not a typical pattern.
The sentiment among these major traders is split, with 10% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $29,218, and 19 calls, totaling $691,985.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $595.0 to $650.0 for UnitedHealth Group over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for UnitedHealth Group options trades today is 516.5 with a total volume of 1,290.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for UnitedHealth Group's big money trades within a strike price range of $595.0 to $650.0 over the last 30 days.
<h3>UnitedHealth Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732038353_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$11.25</td>
<td>$10.35</td>
<td>$10.8</td>
<td>$650.00</td>
<td>$54.0K</td>
<td>394</td>
<td align="right">50</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.15</td>
<td>$7.9</td>
<td>$8.0</td>
<td>$600.00</td>
<td>$49.6K</td>
<td>1.3K</td>
<td align="right">226</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$26.3</td>
<td>$26.1</td>
<td>$26.3</td>
<td>$600.00</td>
<td>$47.3K</td>
<td>707</td>
<td align="right">40</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.2</td>
<td>$8.8</td>
<td>$9.0</td>
<td>$600.00</td>
<td>$44.1K</td>
<td>1.3K</td>
<td align="right">52</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$7.85</td>
<td>$8.0</td>
<td>$600.00</td>
<td>$40.0K</td>
<td>1.3K</td>
<td align="right">226</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Current Position of UnitedHealth Group</h3>
<ul>
<li>Trading volume stands at 998,091, with UNH's price down by -1.4%, positioned at $581.39.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>Professional Analyst Ratings for UnitedHealth Group</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $603.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $603. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Unpacking the Latest Options Trading Trends in UnitedHealth Group

UnitedHealth Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 7.06 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UnitedHealth Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UnitedHealth Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UnitedHealth Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UnitedHealth Group's peer group average for short interest as a percentage of float is 4.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(UNH) - Analyzing UnitedHealth Group's Short Interest

On Tuesday, the U.S. Justice Department said it will block UnitedHealth Group Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) multi-billion&nbsp;acquisition of&nbsp;Amedisys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns about competition in the home <a target="_blank" href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on" rel="noreferrer noopener">health services market</a>.
UnitedHealth&#8217;s Optum unit&nbsp;launched a website&nbsp;that aims to highlight the benefits of the combination. The website <a target="_blank" href="https://www.improvinghomecare.com/" rel="noreferrer noopener">notes</a> that the home healthcare industry remains highly fragmented despite the growing market.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
On average, 26 agencies compete in metropolitan areas with about 500,000 residents, highlighting the range of available care options.
In 2020, approximately 3 million Americans received home health care, a figure expected to grow as the population ages.
By 2030, 18% of the U.S. population will be 65 or older, a significant increase from 13% in 2021.
This demographic shift underscores the necessity for expanded home health services that allow older adults to remain in their homes.
The merger between Optum and Amedisys represents a strategic move to address these needs.
While this combined entity would represent only a portion of the overall home health and hospice care market, the competitive landscape is expected to remain robust.
To promote competition and prevent market dominance, Optum and Amedisys have agreed to divest numerous home health and hospice centers to VitalCaring upon the transaction&#8217;s completion.
VitalCaring currently operates at around 58 locations across six states.
Price Action: UNH stock is down 2.76% at $589.17 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41979149/general-motors-faces-recall-crisis-with-faulty-transmissions-details" target="_blank" rel="noreferrer noopener">General Motors Faces Recall Crisis With Faulty Transmissions: Details</a></li>
</ul>
Image via Shutterstock

UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape

AMZN

AVGO

CPAY

TTWO

Tiger Global 13F Shows Increased Stake In UnitedHealth Group From 2,347,600 To 2,365,400 Shares; Amazon From 6,321,080 To 6,415,488 Shares; Take-Two Interactive Software From 5,643,542 To 5,839,256 Shares; Eli Lilly & Co From 930,000 To 969,800 Shares; Taiwan Semiconductor Manufacturing From 3,070,890 To 3,634,980 Shares; Corpay From 1,046,600 To 1,247,577 Shares; Broadcom From 182,300 To 1,845,500 Shares

UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Movers

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

<a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines">https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines</a>
&nbsp;
The Justice Department on Tuesday sued to block <a href="https://www.wsj.com/market-data/quotes/UNH">UnitedHealth Group</a>'s $3.3 billion acquisition of <a href="https://www.wsj.com/market-data/quotes/AMED">Amedisys</a> alleging the deal would give the <a href="https://www.wsj.com/health/healthcare/unitedhealth-shares-dive-after-health-giant-says-2025-results-likely-to-fall-short-8a7ff76a?mod=article_inline">health-industry giant</a> too much power over the market for home health and hospice services.
The government's move represents an effort to stem the roll-up of different healthcare services under a single owner. UnitedHealth last year acquired one of Amedisys's major competitors, LHC Group.&nbsp;

"Justice Department Sues To Block UnitedHealth's $3.3B Bid For Amedisys; Antitrust Enforcers Argue The Healthcare Giant's Latest Deal Would Illegally Harm Competition" - WSJ

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 28 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 32% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $160,867, and 24 were calls, valued at $6,833,141.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $720.0 for UnitedHealth Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UnitedHealth Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UnitedHealth Group's substantial trades, within a strike price spectrum from $240.0 to $720.0 over the preceding 30 days.
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731434474_0_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$378.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$1.1M</td>
<td>6.0K</td>
<td align="right">30</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">275</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">250</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">225</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>UnitedHealth Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,193,221, with UNH's price down by -1.11%, positioned at $618.3.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 59 days.</li>
</ul>
<h3>What The Experts Say On UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $616.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $625. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $610. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for UnitedHealth Group, targeting a price of $595. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on UnitedHealth Group with a target price of $603. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of UnitedHealth Group's Latest Options Trends

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $146,790, and 9 were calls, valued at $431,920.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $640.0 for UnitedHealth Group during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for UnitedHealth Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across UnitedHealth Group's significant trades, within a strike price range of $300.0 to $640.0, over the past month.
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731337236_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$121.7</td>
<td>$116.45</td>
<td>$120.0</td>
<td>$550.00</td>
<td>$84.0K</td>
<td>173</td>
<td>7</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.35</td>
<td>$5.85</td>
<td>$6.35</td>
<td>$630.00</td>
<td>$63.0K</td>
<td>4.4K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.35</td>
<td>$34.95</td>
<td>$36.24</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>39</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.4</td>
<td>$34.9</td>
<td>$36.23</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>24</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$122.3</td>
<td>$119.2</td>
<td>$122.3</td>
<td>$500.00</td>
<td>$48.9K</td>
<td>2.0K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 206,951, the price of UNH is up 1.22% at $623.31. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>Expert Opinions on UnitedHealth Group</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $627.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $625. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for UnitedHealth Group, targeting a price of $609. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; An analyst from Stephens &amp; Co. has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $605. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

ALHC

CLOV

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 50% bearish. Among these notable options, 16 are puts, totaling $721,919, and 36 are calls, amounting to $2,134,986.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $650.0 for UnitedHealth Group during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale trades within a strike price range from $480.0 to $650.0 in the last 30 days. 
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839752_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.05</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$567.50</td>
<td>$278.8K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.15</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$565.00</td>
<td>$237.6K</td>
<td style="text-align: right;">187</td>
<td style="text-align: right;">158</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$14.95</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$565.00</td>
<td>$145.0K</td>
<td style="text-align: right;">148</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$11.05</td>
<td>$10.7</td>
<td>$11.05</td>
<td>$562.50</td>
<td>$102.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$557.50</td>
<td>$88.5K</td>
<td style="text-align: right;">174</td>
<td style="text-align: right;">97</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,471,322, the price of UNH is up by 1.84%, reaching $568.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $637.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on UnitedHealth Group with a target price of $650. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $595. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at UnitedHealth Group's Options Market Dynamics

<a href="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show" title="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show">https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show</a>

'UnitedHealth Emails Reveal Tension Over Cuts To Doctor Pay; Documents Unsealed In Litigation With A Blackstone-Backed Physician Group Show Controversy Inside The Company Over Reducing Payment Rates' - Bloomberg News

Technology giant NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is set to join the Dow Jones Industrial Average on Nov. 8 replacing Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), a move predicted by several market experts to <a href="https://www.benzinga.com/top-stories/24/05/39011237/exclusive-nvidia-dow-jones-inclusion-a-matter-of-when-will-it-replace-intel">Benzinga months ago.</a>
Here's a look at what the Dow Jones Industrial Average inclusion means for Nvidia and why another addition to the index could be more important.
What Happened: Nvidia <a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">will replace Intel</a> in the Dow Jones Industrial Average, a move that may have been predicted by a 10-for-1 stock split by the tech giant earlier this year.
"Price wise, shares are at that elevated level where they have announced a split in the past. Rumor wise, a stock split would make shares more attractive to be added to the Dow Jones Industrial Average," Freedom Capital Markets Chief Strategist Jay Woods said before the split was announced.
Woods told Benzinga Nvidia was a prime candidate to be included in the Dow Jones Industrial Average, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>).
"When you're the face of the next wave of growth in technology, that being AI, that being the chipmaker, that to me says you should be represented in the Dow Jones Industrial Average," Woods previously told Benzinga.
Launched in 1896, the <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average</a> is a well-known stock market index that includes 30 blue-chip U.S. companies. The index often changes to include the best barometers of American growth.
One of the key differences between the Dow Jones Industrial Average and other market indexes like the S&amp;P 500 is the Dow is price-weighted and does not account for changes in market capitalization.
This means that company's that have higher share prices have larger weightings than those with smaller stock prices. So while Nvidia's stock split may have helped the company get into the index, it will now hurt the company's position in the index.
Based on data from <a href="https://www.slickcharts.com/dowjones">Slickcharts</a>, Nvidia would be the 21st largest company by weighting in the index if it were added today. The stock would position after Chevron ($153.33) and ahead of 3M Co ($126.94) with a price of $138.76 at the time of writing. Nvidia would have an estimated weighting of between 1.98% and 2.38% based on the current weighting of 3M and Chevron respectively.
Compare that to UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), currently the largest weighting in the Dow Jones Industrial Average at $556.81 and 8.8%.
Intel, which is being replaced by Nvidia, is currently ranked last in the index with a price of $22.54 and weighting of 0.36%.
As one of the largest companies in the world, Nvidia is the second largest weighting in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, representing 6.8% of assets in the ETF. Nvidia is also the second largest weighting in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), which tracks the tech sector, with the stock having a weighting of 14.25%.
Are you buying when the CEOs of the Magnificent 7 are selling?Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a>
Another Dow Index Addition: While investors are excited about Nvidia joining the Dow Jones Industrial Average, they might want to look at Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), which will have a large weighting in the index and see heavier buying from ETFs that cover the index.
Sherwin-Williams has a current share price of $372.97, which will give the company a higher weighting in the index. The stock would currently rank sixth in the index between Caterpillar ($377.72) and Amgen ($317.75). If Sherwin-Williams were added today, the stock would have an estimated weighting of between 4.97% and 5.91%.
Sherwin-Williams is replacing Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) in the index, which currently ranks 28th with a price of $48.10 and a weighting of 0.76%.
The new weightings will depend on prices ahead of the Nov. 8 changes and also be impacted by two of the smaller holdings exiting the index.
Why It's Important: Intel has been a member of the Dow Jones Industrial Average since 1999 but has lagged in stock performance in recent years.
Nvidia is more relevant than Intel and used by the biggest companies, Woods previously told Benzinga.
"The growth is there, the story is there, and now the price is there," Woods said.
Benzinga's "PreMarket Prep" co-host Dennis Dick also predicted Nvidia replacing Intel in the index earlier this year.
"I'd expect this announcement sometime in the summer. I don't think it's a matter of ‘if' NVDA goes into the Dow, I think it's now a matter of ‘when,'" Dick said.
Nvidia shares are up 188.1% year-to-date in 2024 and up 2,573.6% over the past five years. Intel stock is down 52.9% year-to-date in 2024 and down 61.4% over the past five years.
Sherwin-Williams stock is up 22.3% year-to-date in 2024 and up 92.5% over the past five years. Dow stock is down 14.0% year-to-date in 2024 and down 15.0% over the last five years.
The negative performance for Intel and Dow may explain why the Dow Jones Industrial Average has underperformed the S&amp;P 500 index. The Dow Jones Industrial Average ETF is up 11.1% year-to-date and up 51.2% over the past five years. Compare that to the SPY, which is up 20.8% year-to-date and up 84.9% over the past five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
Photo: Shutterstock

Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 20 years by 5.85% on an annualized basis producing an average annual return of 14.17%. Currently, UnitedHealth Group has a market capitalization of $519.85 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 20 years ago, it would be worth $1,416.61 today based on a price of $562.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730320221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 20 Years

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) against its key competitors in the Health Care Providers &amp; Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>UnitedHealth Group Background</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc</td>
<td>36.55</td>
<td>5.20</td>
<td>1.34</td>
<td>4.79%</td>
<td>$7.67</td>
<td>$21.06</td>
<td>6.61%</td>
</tr>
<tr>
<td>Centene Corp</td>
<td>10.47</td>
<td>1.12</td>
<td>0.20</td>
<td>4.22%</td>
<td>$2.0</td>
<td>$4.43</td>
<td>5.92%</td>
</tr>
<tr>
<td>Molina Healthcare Inc</td>
<td>16.44</td>
<td>3.87</td>
<td>0.48</td>
<td>6.78%</td>
<td>$0.51</td>
<td>$1.19</td>
<td>20.96%</td>
</tr>
<tr>
<td>HealthEquity Inc</td>
<td>72.60</td>
<td>3.53</td>
<td>6.98</td>
<td>1.68%</td>
<td>$0.11</td>
<td>$0.2</td>
<td>23.15%</td>
</tr>
<tr>
<td>Progyny Inc</td>
<td>24.83</td>
<td>3.10</td>
<td>1.38</td>
<td>3.21%</td>
<td>$0.02</td>
<td>$0.07</td>
<td>8.85%</td>
</tr>
<tr>
<td>Average</td>
<td>31.08</td>
<td>2.9</td>
<td>2.26</td>
<td>3.97%</td>
<td>$0.66</td>
<td>$1.47</td>
<td>14.72%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining UnitedHealth Group, the following trends can be inferred: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 36.55, is 1.18x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
The elevated Price to Book ratio of 5.2 relative to the industry average by 1.79x suggests company might be overvalued based on its book value.
</li>
<li>
With a relatively low Price to Sales ratio of 1.34, which is 0.59x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 4.79%, which is 0.82% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
Compared to its industry, the company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.67 Billion, which is 11.62x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $21.06 Billion, which indicates 14.33x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 6.61% is significantly below the industry average of 14.72%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730300423_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By evaluating UnitedHealth Group against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:
<ul>
<li>
Among its top 4 peers, UnitedHealth Group has a higher debt-to-equity ratio of 0.84.
</li>
<li>
This suggests a greater reliance on debt financing, which can expose the company to increased financial risk and potential volatility.
</li>
</ul>
<h3>Key Takeaways</h3>
For UnitedHealth Group, the PE, PB, and PS ratios indicate high valuation compared to peers in the Health Care Providers &amp; Services industry. This suggests potential overvaluation based on these metrics. On the other hand, the high ROE, EBITDA, and gross profit, along with low revenue growth, highlight strong profitability and operational efficiency relative to industry competitors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: UnitedHealth Group Versus Competitors In Health Care Providers &amp; Services Industry

Franklin Growth Opportunities Fund Q3 2024 Commentary

Franklin Corefolio Allocation Fund Q3 2024 Commentary

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Transition team weighing White House crypto role

Optimism over global healthcare sector rises: Jefferies

UnitedHealth Group: Preparing For December Investor Day, Buy Reiterated

UnitedHealth: Navigating Policy Uncertainty Well, Solid EPS Growth Ahead

UnitedHealth Group: Now A Fairly Valued Dividend-Growth Machine

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

U.S. Managed Care Q3 2024 Earnings Recap: Medicaid/Medicare Costs Mount

UnitedHealth wins Star Ratings lawsuit against Medicare

AAPL

ABBV

AMGN

ASML

AXON

BIIB

BITF

BTBT

COIN

CORZ

CRKN

CRWD

GILD

GOOG

GOOGL

GREE

MARA

MPWR

MRNA

MSFT

MSTR

ONON

ORCL

PINS

RIOT

SDIG

SNYNF

WING

WULF

Press Releases

UNITEDHEALTH GROUP INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group and Goodwill® Partner to Expand Career Pathways Training to Foster Healthier Communities

UNITEDHEALTH GROUP INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group Announces Earnings Release Date

UnitedHealthcare Community Plan of New Mexico invests $250,000 to provide integrated health care services to K-12 students

UNITEDHEALTH ALERT: Bragar Eagel & Squire, P.C. is Investigating UnitedHealth Group Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

UnitedHealthcare Commits $335,000 to Idaho Organizations To Expand Health Care Workforce and Access To Care

UnitedHealth Group Reports Third Quarter 2024 Results

UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Humana

Molina Healthcare

NeueHealth

Progyny

Barclays

TD Cowen

Stephens & Co.

Cantor Fitzgerald

United HealthCare

기술 대기업인 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 다우존스 산업평균지수에 11월 8일 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)을 대체하여 합류할 예정이다. 이는 여러 시장 전문가들에 의해 몇 달 전 <a href="https://www.benzinga.com/top-stories/24/05/39011237/exclusive-nvidia-dow-jones-inclusion-a-matter-of-when-will-it-replace-intel">벤징가</a>에 의해 예측된 바 있다.
다음은 다우존스 산업평균지수에 포함된 것이 엔비디아에게 의미하는 바와 다른 주식의 이 지수에 추가가 왜 더 중요할 수 있는지에 대한 설명이다.
무슨 일이 있었나요: 엔비디아는 <a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">다우존스 산업평균지수에서 인텔을 대체</a>할 예정이며, 이는 올해 초 기술 대기업의 10대 1 주식 분할에 의해 예측되었을 수도 있다.
&#8220;가격적으로 주가가 과거에 분할을 발표한 적이 있는 높은 수준에 있다. 소문으로 보면 주식 분할은 주식을 다우존스 산업평균지수에 추가하기 더 매력적으로 만들 것이다&#8221;고 프리덤 캐피털 마켓(Freedom Capital Markets)의 수석 전략가 제이 우즈(Jay Woods)가 분할 발표 이전에 말했다.
우즈는 벤징가에 엔비디아가 SPDR Dow Jones Industrial Average ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)가 추적하는 다우존스 산업평균지수에 포함되기 위한 최적의 후보라고 말했다.
&#8220;당신이 기술의 다음 성장 파도의 얼굴이자 인공지능(AI)와 칩 제조사라면, 당신은 다우존스 산업평균지수에 포함되어야 한다고 생각한다&#8221;고 우즈가 이전에 벤징가에 말했다.
1896년에 출시된 <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">다우존스 산업평균지수</a>는 30개의 블루칩 미국 기업들이 포함된 잘 알려진 주식 시장 지수이다. 이 지수는 종종 미국 성장의 가장 좋은 기준들을 포함하도록 변경된다.
다우존스 산업평균지수와 S&amp;P 500과 같은 다른 시장 지수들의 주요 차이점 중 하나는 다우가 가격 가중치 지수이며 시장 자본금의 변화를 고려하지 않는다는 것이다.
즉, 주가가 높은 회사가 낮은 회사보다 더 큰 비중을 차지한다. 따라서 엔비디아의 주식 분할이 회사가 지수에 포함되는 데 도움을 주었을 수 있지만, 이제는 지수 내 회사의 위치에 해를 끼칠 것이다.
슬릭차트(<a href="https://www.slickcharts.com/dowjones" target="_blank" rel="noopener">Slickcharts</a>)의 데이터에 따르면, 엔비디아가 오늘 추가된다면 지수에서 21위로 평가될 것이다. 주가가 작성 시점에 $138.76인 경우 쉐브론($153.33) 다음과 3M($126.94) 이전에 위치하게 된다. 또한, 엔비디아의 추정 비율은 3M과 쉐브론의 현재 비중에 따라 각각 1.98%와 2.38% 사이로 평가될 것다.
현재 다우존스 산업평균지수에서 가장 큰 비중을 차지하는 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)의 주가가 $556.81이고 비중이 8.8%이다.
인텔은 엔비디아로 대체되고 있으며 현재 주가가 $22.54이고 지수에서 0.36%로 가장 낮은 순위를 차지하고 있다.
엔비디아는 세계에서 가장 큰 회사 중 하나이며, S&amp;P 500 지수를 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)에서 두 번째로 큰 비중을 차지하고 있으며, 이 ETF 자산의 6.8%를 나타낸다. 또한, 엔비디아는 Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)에서 두 번째로 큰 비중을 차지하고 있으며, 주식의 비중은 14.25%이다.
CEO들이 매도할 때 당신은 사고 있습니까? 인사이더 트레이드 페이지에서 최신 정보를 확인하세요 — <a href="https://www.benzinga.com/sec/insider-trades/">마크 저커버그, 일론 머스크, 젠슨 황과 같은 리더들이 자신의 주식을 매도할 때를 확인하세요.</a>
또 다른 다우 지수 추가: 투자자들이 엔비디아가 다우존스 산업평균지수에 합류하는 것에 흥분하고 있는 반면, 셔윈 윌리엄즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)를 주목할 필요가 있다. 이 회사는 이 지수에서 큰 비중을 차지하고 있으며, 이 지수를 커버하는 ETF들에서 더 많은 구매가 이루어질 것이다.
셔윈 윌리엄즈의 현재 주가가 $372.97로, 이는 회사에게 지수에서 더 높은 비중을 부여할 것이다. 주가가 현재 캐터필러($377.72)와 암젠($317.75) 사이의 여섯 번째로 평가될 것이다. 만약 오늘 셔윈 윌리엄즈가 추가된다면, 주식의 비중은 4.97%와 5.91% 사이로 추정될 것이다.
셔윈 윌리엄즈는 현재 주가가 $48.10이고 비중이 0.76%로 지수에서 28위인 다우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)를 대체하고 있다.
이 새로운 비중은 11월 8일 변경 이전의 가격에 따라 달라지며, 이 지수에서 두 개의 작은 주식들이 퇴출되는 영향도 받는다.
왜 중요한가 (Why It&#8217;s Important): 인텔은 1999년부터 다우존스 산업평균지수의 일원이었지만, 최근 몇 년간 주식 성과가 저조했다.
엔비디아는 인텔보다 더 관련성이 높고 가장 큰 회사들에 의해 사용된다고 우즈는 이전에 벤징가에 말했다.
&#8220;성장이 있으며, 이야기가 있으며, 이제 가격이 있다&#8221;고 우즈가 말했다.
벤징가의 &#8220;프리마켓 프렙&#8221; 공동 진행자인 데니스 딕(Dennis Dick)도 올해 초 엔비디아가 인텔을 대체할 것이라고 예측했다.
&#8220;여름쯤에 이 발표가 있을 것으로 예상한다. 엔비디아가 다우에 포함될지의 문제가 아니라 언제 포함될지가 문제라고 생각한다&#8221;고 딕이 말했다.
엔비디아의 주식은 2024년 현재 188.1% 상승했으며, 지난 5년 동안 2,573.6% 상승했다. 인텔 주식은 2024년 현재 52.9% 하락했으며, 지난 5년 동안 61.4% 하락했다.
셔윈 윌리엄즈의 주식은 2024년 현재 22.3% 상승했으며, 지난 5년 동안 92.5% 상승했다. 다우 주식은 2024년 현재 14.0% 하락했으며, 지난 5년 동안 15.0% 하락했다.
인텔과 다우의 부정적인 성과는 다우존스 산업평균지수가 S&amp;P 500 지수보다 저조한 성과를 보인 이유를 설명할 수 있다. 다우존스 산업평균지수 ETF는 2024년 현재 11.1% 상승했으며, 지난 5년 동안 51.2% 상승했다. SPY와 비교하면, SPY는 2024년 현재 20.8% 상승했으며, 지난 5년 동안 84.9% 상승했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">독점: 2024년 10월 벤징가 프로에서 가장 많이 검색된 티커 20개 — 테슬라, 엔비디아, 애플, DJT 주식은 어디에 위치하나요?</a></li>
</ul>
사진 출처: Shutterstock

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.
콜럼버스 데이는 1492년 크리스토퍼 콜럼버스의 북미 착륙을 기념하는 연방 공휴일로, 뉴욕 증권 거래소와 나스닥 주식 시장은 평소와 같이 운영된다. 장외(OTC) 시장도 개방되지만, 채권 시장은 휴장한다. 미국 우편 서비스와 연방 준비 제도도 운영되지 않으며, 많은 은행도 이를 따른다.
일부 주에서는 이 날을 원주민 공동체의 회복력을 기념하는 원주민의 날로 인정하기도 한다.
참고: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 이더리움, 도지코인이 금요일 상승을 보였지만, 트레이더는 &#8216;59,000달러는 유지되어야 한다&#8217;고 경고했다.</a>
국제적으로는 대부분의 시장에서 거래가 평소와 같이 계속되지만, 토론토 증권 거래소는 캐나다 추수감사절을 기념하여 휴장한다.
투자자들은 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 대만 반도체 제조(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)와 같은 주요 기업들의 실적 발표가 있는 바쁜 주를 대비해야 한다. 또한, 실업 수당 청구, 소매 판매, 주택 착공 등의 주요 경제 지표 발표가 현재 경제 상태에 대한 통찰력을 제공할 것이다.
가격 동향: 작성 시점에 월요일 프리마켓에서 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 약 0.22% 상승하여 약간 높은 가격으로 거래되었으며, Invesco QQQ Trust, Series 1(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.32% 상승했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">저스틴 비버의 2024년 크립토 수익 – 팝 아이콘이 그의 이더리움 투자로 얼마나 벌었는지 알아보세요!</a></li>
</ul>
이미지 출처: Shutterstock
이 콘텐츠는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>가 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 연방거래위원회(FTC)가 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) 및 시그나 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)의 처방약급여관리업체(PBM)들을 철저히 조사하고 있는 가운데, 투자자들은 어떤 의료 대기업이 <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noopener">이 위기를 가장 잘 이겨낼 수</a> 있을지 궁금해하고 있다.
인슐린 가격을 부풀린 혐의로 이들 회사를 <a href="https://www.cnbc.com/2024/09/20/ftc-sues-drug-middlemen-for-allegedly-inflating-insulin-prices.html" target="_blank" rel="noopener">대상으로</a> 한 이번 FTC의 소송은 의료 산업 전반에 큰 파급 효과를 미칠 수 있으며 이는 주식 변동성을 의미한다.
그래서, 어떤 주식이 더 건강해 보일까?
<h2 class="wp-block-heading">유나이티드헬스 그룹: 규모가 크고 대담하지만 면밀히 조사받고 있다</h2>
유나이티드헬스 그룹의 옵텀RX(OptumRx) 부문이 FTC 소송의 핵심에 있으며, UNH의 글로벌 의료 리더로서의 막대한 규모는 많은 힘을 부여하지만, 동시에 큰 표적이 되기도 한다.
애널리스트들은 향후 12개월 동안 주가가 <a href="https://www.benzinga.com/report/UNH" target="_blank" rel="noopener">2.75%</a> 정도 움직일 것으로 예상하며, 목표 주가는 591달러에서 680달러 사이이다. 유나이티드헬스의 규모는 FTC의 결정에 따라 방패 역할을 할 수도 있고, 발목을 잡을 수도 있다.
현재로서는 이 회사는 헤비급 챔피언이지만, 그 부피가 규제적 타격을 피하는 데 도움이 될지는 두고 봐야 한다.
참고 기사: <a href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars">유나이티드헬스, 경쟁사들을 따라가며 휴미라를 저가형 바이오시밀러로 대체</a>
<h2 class="wp-block-heading">CVS 헬: 소매의 회복력 또는 규제의 걸림돌?</h2>
9,000개가 넘는 약국 지점과 PBM 사업 케어마크(Caremark)로 유명한 CVS 헬스도 겨냥당하고 있다.
애트나(Aetna)와의 통합 및 최근 오크 스트리트(Oak Street) 인수는 위험 확산에 도움이 될 수 있지만 운영의 ​​복잡성으로 인해 더 많은 규제 조사가 필요하다.
애널리스트들은 약 6.36%의 주가 변동을 예상하고 있으며, <a href="https://www.benzinga.com/report/CVS" target="_blank" rel="noopener">12개월 목표 주가는 63달러</a>이다. CVS는 다각화된 플레이어이지만, 만능형이 되는 것은 규제 미로를 탐색하는 것을 더욱 복잡하게 만들 수 있다.
<h2 class="wp-block-heading">시그나: 틈새 집중, 더 큰 움직임?</h2>
시그나는 주목해야 할 언더독일 수 있다. 이 회사의 PBM 부문인 익스프레스 스크립츠(Express Scripts)는 주요 플레이어이지만, 시그나는 자가 보험 플랜 및 주요 정부 계약을 통한 보다 집중된 접근 방식으로 더 큰 경쟁사들보다 쉽게 전환할 수 있을 것이다.
애널리스트들은 시그나의 주가가 <a href="https://www.benzinga.com/report/CI" target="_blank" rel="noopener">14.22%</a> 정도 움직일 것으로 예상하며, 목표 주가는 400달러에서 438달러 사이이다. 시그나는 더 넓은 건강 보험 시장에서 더 작은 입지를 가지고 있어 최악의 규제적 여파를 피할 수 있고, 반격할 수 있을 것으로 보인다.
<h2 class="wp-block-heading">누가 우위를 점할까?</h2>
이 의료 주식 대결에서 승자는 이 회사들이 FTC의 증가하는 조사에 얼마나 잘 적응할 수 있는지에 달려 있다.
유나이티드헬스의 규모는 강점을 제공하지만 더 큰 타깃이 될 수도 있다. CVS는 다양한 포트폴리오를 보유하고 있지만 복잡성으로 인한 위험에 직면해 있다. 시그나는 규모는 작지만 가장 큰 가격 변동에 대비한 것으로 보이며 규제 역풍을 처리하는 데 가장 민첩할 수 있다.
투자자들은 이 법적 상황이 어떻게 전개되는지 주의 깊게 지켜봐야 하며, 더 많은 드라마가 기다리고 있다!

다음 기사 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40957261/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields">월가의 가장 정확한 애널리스트들이 3개의 헬스 케어 주식에 대해 3% 이상의 배당 수익률을 평가</a></li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/39838603" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">기존 텔레비전 네트워크</a>에서 디지털 스트리밍 및 스튜디오 사업을 분할하려는 계획을 논의했다는 보고 이후 18.28% 상승했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 지난주 비트코인 가격의 상승 속에서 16.74% 상승했다.</li>
<li>D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 FY24 지침을 수정한 후 12.91% 급등했다. 회사는 또한 <a href="https://www.benzinga.com//node/39845136" target="_blank" rel="noreferrer noopener">새로운 40억 달러 규모의</a> 자사 주식 매입을 승인했다. 주식에 대한 목표 주가를 <a href="https://www.benzinga.com/quote/dhi/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>을 한 분석가는 거의 없다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 지난주 비트코인 가격 상승의 영향으로 12.39% 상승했다.</li>
<li>블루 아울 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OQL#NYSE">OQL</a>)은 블룸버그가 아탈라야(Atalaya)를 약 8억 달러에 매수할 계획이라고 <a href="https://www.bloomberg.com/news/articles/2024-07-16/blue-owl-to-buy-private-credit-firm-atalaya-adding-10-billion-in-assets?sref=2h1zKciy" target="_blank" rel="noreferrer noopener">발표</a>한 후 7.89% 상승했다.</li>
<li>유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)의 주가는 <a href="https://www.benzinga.com//node/39790051" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적 호조</a>에 따라 7.84% 상승했다. 많은 분석가들이 주식에 대한 가격 예측을 <a href="https://www.benzinga.com//node/39814804" target="_blank" rel="noreferrer noopener">상향 조정했</a>다.</li>
<li>스테이트 스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>)는 예상보다 나은 <a href="https://www.benzinga.com//node/39795949" target="_blank" rel="noreferrer noopener">2분기</a> 실적에 힘입어 7.21% 급등했다. 몇몇 분석가들은 주식 가격 예측을 <a href="https://www.benzinga.com//node/39822388" target="_blank" rel="noreferrer noopener">수정</a>했다. </li>
<li>레나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)는 다른 주택 건설업체 주식들과의 공감을 이유로 7.07% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)는 미즈호(Mizuho)가 주식을 중립에서 아웃퍼폼(Outperform)으로 <a href="https://www.benzinga.com/quote/TOST/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정하고</a> 목표 주가를 21달러에서 33달러로 상향 조정한 후 지난주 주가는 7.05% 상승했다. </li>
<li>이팸 시스템(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)의 주식은 제프리스(Jefferies)의 분석가가 <a href="https://www.benzinga.com/quote/epam/analyst-ratings" target="_blank" rel="noreferrer noopener">보유에서 매수로</a> 등급을 올린 후 6.97% 상승했다.</li>
</ol>
사진=Shutterstock의 rafapress






Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

EPAM

INFY

LEGN

TOST

VTRS

워너 브라더스와 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 14일-7월 20일)

다우존스 산업평균지수는 수요일 0.6% 상승한 41,198포인트로 새로운 사상 최고치를 경신하며 <a href="https://www.benzinga.com/topic/dow-jones-industrial-average" target="_blank" rel="noopener" data-google-interstitial="false">6일 연속 상승</a>하여 마감했다.
SPDR Dow Jones Industrial Average ETF(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/dia" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for DIA">DIA</a>)가 추적하는 우량주는 7월 계절성에 강력한 동맹을 찾았다. 불과 1년 전, 다우존스 지수는 7월 10일부터 13회 연속 놀라운 강세장을 시작했다.
올해 다우 랠리는 최고 기록을 세웠을 뿐만 아니라 기술 부문에 비해 뛰어난 성과를 냈다는 점에서도 두드러졌다.
지난 6거래일 동안 다우존스 지수는 5% 상승한 반면, 기술주 중심의 나스닥 100 지수는 3.3% 하락했다. 따라서 최근 6번의 세션에서 나스닥 100을 8.3%포인트 앞섰다.
블루칩이 기술주를 이토록 앞지른 또 다른 6일의 기간을 찾으려면 2002년 7월로 돌아가야 한다.
<h3 class="wp-block-heading">다우존스 vs. 나스닥100</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-441691" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29-1024x456.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29-1024x456.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29-300x134.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29-768x342.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29-1536x684.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17162751/image-29.png 1920w" alt="" width="1024" height="456" /></figure>
찰스 슈왑(Charles Schwab)의 트레이딩 및 교육 담당 이사인 조 마졸라(Joe Mazzola)는 현재 &#8220;경제 성장에 가장 잘 맞는 산업재 및 소재와 같은 경기 순환 부문에 대한 일반적인 열정&#8221;이 있다고 말한다. &#8220;9월부터 시작되는 연방준비제도(연준)의 금리 인하 희망은 지난주 말부터 해당 부문으로의 대대적인 순환을 촉발시켰다.&#8221;
"다우존스 산업평균지수가 새로운 최고치를 경신해 2024년 여름 랠리가 더욱 견고해지고 있음을 시사했다"고 CFA, CMT의 스티븐 수트마이어(Stephen Suttmeier)가 말했다.
<h3 class="wp-block-heading">최근 5일 세션의 최고 5개 블루칩 주식</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>이름</td>
<td>주가 변동률 % (5일)</td>
</tr>
<tr>
<td>유나이티드헬스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>14.43%</td>
</tr>
<tr>
<td>캐터필러 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</td>
<td>8.91%</td>
</tr>
<tr>
<td>홈 디포 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</td>
<td>8.11%</td>
</tr>
<tr>
<td>다우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>7.16%</td>
</tr>
<tr>
<td>트래블러스 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)</td>
<td>6.47%</td>
</tr>
</tbody>
</table>
</figure>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39823332/nasdaq-100-suffers-worst-day-in-11-months-as-chipmakers-tumble-on-china-curbs-magnificent-">칩 제조업체들이 중국 제재로 급락하자 </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39823332/nasdaq-100-suffers-worst-day-in-11-months-as-chipmakers-tumble-on-china-curbs-magnificent-">나스닥 100은 </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39823332/nasdaq-100-suffers-worst-day-in-11-months-as-chipmakers-tumble-on-china-curbs-magnificent-">11개월 만에 최악의 날을 경험. 매그니피센트 세븐, 5,000억 달러 손실</a></li>
</ul>
출처: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다우존스 사상 최고치 경신: 블루칩은 22년 만에 기술주 대비 가장 강한 6일 상승세 기록

화요일 오전 (미 동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 주식 중 일부는 다음과 같다:
<ul>
<li>월스트리트는 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)가 개장 전에 252억 2천만 달러의 매출과 주당 80센트의 분기 이익을 보고할 것으로 예상하고 있다. 뱅크 오브 아메리카의 주식은 시간외 거래에서 0.1% 상승한 41.94달러를 기록했다.</li>
<li>FB 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>)은 월요일에 예상보다 나은 2분기 실적을 발표했다. FB 금융 주가는 시간외 거래에서 0.5% 상승한 43.03달러를 기록했다.</li>
<li>분석가들은 모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)가 매출 143억 달러, 주당 1.65달러의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 열리기 전에 수익을 발표할 예정이다. 모건 스탠리의 주가는 시간외 거래에서 0.8% 상승한 106.14달러를 기록했다.</li>
</ul>
당사의 <a href="https://www.benzinga.com/premarket/">프리마켓 시장 뉴스를 확인하세요.</a>
<ul>
<li>카이버나 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>)는 불응성 강직증후군 환자 치료에 대해 KYV-101이 FDA 재생의학 첨단치료제로 지정되었다고 발표한 후 월요일 시간외 거래에서 급등했다. 카이버나의 주가는 시간외 거래에서 7.5% 상승한 10.65달러를 기록했다.</li>
<li>분석가들은 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)가 시장 마감 후 988억 4천만 달러의 매출과 주당 6.66달러의 분기 이익을 발표할 것으로 예상한다. 유나이티드헬스의 주가는 시간외 거래에서 0.9% 상승한 519.99달러를 기록했다.</li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Earnings

Equities

Pre-Market Outlook

KYTX

화요일 주목해야 할 주식: 뱅크 오브 아메리카, 모건 스탠리 그리고 3종목

유나이티드헬스 그룹((UnitedHealth Group, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)은 자회사인 체인지 헬스케어(Change Healthcare)에 대한 2월 사이버 공격에 따라 사이버 위협 행위자들에게 몸값을 지불했다고 월요일 밝혔다.
이 회사는 해당 사건으로 인해 개인 데이터가 <a href="https://www.benzinga.com/news/large-cap/24/04/38363718/unitedhealth-ceo-to-testify-before-us-house-panel-regarding-cyberattack-on-technology-unit" target="_blank" rel="noreferrer noopener">유출</a>되었음을 인정했다.
이 회사가 몸값으로 지불한 정확한 금액을 공개하지 않았음에도 불구하고 이러한 인정은 공격의 심각성을 강조한다. 1억 5,200만 명 이상의 고객을 보유한 유나이티드헬스는 사건을 철저히 조사하기 위해 법 집행 기관 및 사이버 보안 회사와의 지속적인 협력을 강조했다.
CNBC에 제공된 <a href="https://www.cnbc.com/2024/04/22/unitedhealth-paid-ransom-to-bad-actors-says-patient-data-was-compromised-in-change-healthcare-cyberattack.html" target="_blank" rel="noopener noreferrer">발표</a>에 따르면 이 공격은 악의적인 위협 행위자들에 의해 조직되었으므로 환자 데이터에 미치는 영향을 완화하기 위한 신속한 조치가 필요했다.
이 문제는 유나이티드헬스 고객을 넘어 확장되어 잠재적으로 미국 인구의 상당 부분에 영향을 미칠 수 있다.
의료 부문 내 결제 및 매출 주기 관리의 중요한 역할을 하는 체인지 헬스케어는 매년 150억 건 이상의 거래를 처리한다.
이렇게 널리 영향력을 가진 곳에서는 유나이티드헬스의 고객이 아닌 사람들까지 자료 유출의 위험을 받았을 수 있다.
이 문제에 대응하여 유나이티드헬스는 2년 동안 신원 도용 보호 및 신용 모니터링을 제공하는 전용 웹사이트와 콜센터를 구축하는 등 피해를 입은 개인을 지원하기 위한 조치를 취했다.
그러나 이 상황이 복잡한 만큼, 이 회사는 개별 데이터의 영향에 대한 구체적인 세부 사항을 제공하기에는 제한이 있다고 언급했다.
로이터는 유나이티드헬스가 이 사건에 대한 자료의 철저한 분석을 위해서는 &#8220;몇 달&#8221;이 걸릴 것으로 언급했지만, 의사의 차트나 개인의 완전한 의료 기록에 영향을 미친 것으로 추정되는 바는 없다고 밝혔다.
이 회사는 피해자의 정확한 수치에 대해서는 명시하지 않았지만, 해커들이 이와 같은 데이터 패킷을 보통 배포하거나 교환하는 온라인 포럼을 적극적으로 모니터링하고 있다고 언급했다.
유나이티드헬스는 유출된 파일을 보여주는 것으로 추정되는 22개의 스크린샷이 다크 웹에서 공유되었다고 보고했다.
그들은 추가 데이터가 노출되지 않았으며, 의사의 차트나 완전한 의료 기록이 유출된 증거가 없다고 약속했다.
가격 움직임: 유나이티드헬스의 주식은 화요일 1.03% 하락한 486.18달러에 마감했다.
면책 조항 이 콘텐츠는 인공지능 도구의 도움을 받아 제작된 부분이 포함되어 있으며 Benzinga 편집인들에 의해 검토되고 발행되었습니다.
사진: Pixabay의 B_A

환자 데이터 침해 - 유나이티드헬스 그룹, 사이버공격으로 인한 랜섬 지불 시인

지난주 이들 7개 대형주는 최고의 성과를 냈다. 여러분의 포트폴리오에는 포함된 종목이었나요?
<ol>
<li>유나이티드 항공(에어라인) 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)의 주가는 1분기 실적 발표 이후 지난주 21.79% 급등했다. 매출은 125억 3900만 달러로 컨센서스 추정치 124억 달러를 상회했으며, 조정 주당 손실은 0.15달러로 추정치 0.57달러를 <a href="https://www.benzinga.com/news/earnings/24/04/38291030/why-united-airlines-stock-is-rising-wednesday" target="_blank" rel="noreferrer noopener">상회</a>했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/UAL/analyst-ratings" target="_blank" rel="noreferrer noopener"> 예상</a>을 높였다.</li>
<li>유나이티드헬스그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)은 1분기에 기대 이상의 매출을 올린 덕분에 지난주 주가가 12.43% 상승하였다. 이 회사는 여전히 자회사인 체인지 헬스케어(<a href="https://www.benzinga.com/news/earnings/24/04/38267213/investors-cheer-unitedhealths-q1-earnings-despite-cyberattack-fallout-taking-872m-hit-from-hack" target="_blank" rel="noreferrer noopener">Change Healthcare</a>)에 대한 지난 2월의 사이버 공격 문제를 처리 중에 있다.</li>
<li>제뉴인 파츠 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>)의 주식은 1분기 보다 예상이 더 나은 실적 발표 이후 10.07%의 상승했다. <a href="https://www.benzinga.com/news/earnings/24/04/38316106/why-genuine-parts-shares-are-rising-today-after-q1-earnings" target="_blank" rel="noreferrer noopener">그리고 연간 수익 전망을 상향</a>했다.</li>
<li>벤틀리 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>)의 주식은 지난주 7.94% 상승했다. 프랑스의 산업 거인인 슈나이더 일렉트릭 SE(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SBGSY#OTC">SBGSY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SBGSF#OTC">SBGSF</a>)가 <a href="https://www.benzinga.com/markets/equities/24/04/38333524/whats-going-on-with-bentley-systems-stock-amid-multibillion-dollar-merger-talks" target="_blank" rel="noreferrer noopener">벤틀리 시스템즈의 잠재적 인수에 대한 논의를 확인</a>한 것으로 알려졌다.</li>
<li>엘리밴스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)의 주식은 지난주 5.15% 상승했다. 이 회사는 1분기 메디케이드 등록자 수가 21% 감소하였으나 22억 달러의 1분기 순 이익을 발표하고 연간 지침을 상향했다.  이 주식에 대해 몇몇 애널리스트들은 <a href="https://www.benzinga.com/quote/ELV/analyst-ratings" target="_blank" rel="noreferrer noopener">예상치를 높였다</a>.</li>
<li>프로그레시브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>)의 주식은 지난주 3.34% 상승했다. 이 회사는 1분기 순 보험료가 전년 동기대비 19% 성장하였다. 몇몇 애널리스트들은 이 <a href="https://www.benzinga.com/quote/PGR/analyst-ratings" target="_blank" rel="noreferrer noopener">주식에 대한 예상치를 높였다</a>.</li>
<li>모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)의 주식은 지난주 예상보다 좋은 1분기 실적을 발표한 후 3.3% 상승했다. 이 투자은행의 <a href="https://www.benzinga.com//node/38272690" target="_blank" rel="noreferrer noopener">매출은 전년 대비 16% 증가했다</a>. 이 은행은 또한 APC 지역의 직원을 <a href="https://www.benzinga.com//node/38287804" target="_blank" rel="noreferrer noopener">줄이기로 결정했다</a>.</li>
</ol>
참고 사항: <a href="https://www.benzinga.com/news/large-cap/24/04/38348564/lets-spill-the-tea-top-consumer-tech-news-you-should-know-from-last-week" target="_blank" rel="noopener">지난주에 발표된 소비자 기술 뉴스의 주요 내용을 알고 싶다면</a>
사진: 셔터스톡

SBGSF

SBGSY

지난주 최고 성과 주식: 이 7개의 대형주가 포트폴리오에 포함되어 있나요?

월요일 시간외 거래에서 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)와 CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)를 포함한 여러 의료 보험 회사들의 주가가 하락했다. 이는 메디케어 및 메디테이드서비스 센터(CMS)가 <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-payment-updates-2025-medicare-advantage-and-medicare-part-d-programs">결제 업데이트를 확정</a>한 후 발생한 일이다.
사건의 전말: CMS는 월요일, 메디케어 어드밴티지(MA) 및 메디케어 파트 D 처방약(파트 D) 프로그램에 대한 2025년도 요율 발표를 확정하고 이 프로그램에 대한 결제 정책을 업데이트하고 결제 정확도를 보장하도록 했다고 발표했다.
이번 요율 발표에 따르면, 2024년부터 2025년까지 평균적으로 정부로부터 MA 계획에 대한 지급이 3.7% 증가할 것으로 예상된다. 또한 2025 년 미 연방정부는 사설 보험 계획에 대해 500 ~ 600 억 달러 사이의 MA 지급을 예상하고 있다.
CMS는 또한 2025년 메디케어 파트 D 약물 혜택 구조를 개선하여 약값을 낮출 예정이라고 밝혔다. 2025년에 메디케어 파트 D를 가입한 사람들의 연간 최대 부담 비용은 2,000 달러로 제한될 것이다.
&#8220;대통령의 하위 처방약에 대한 비용을 낮추게 해주는 인플레이션 감축법(IRA) 덕분에 다음 해에 메디케어 파트 D를 가입한 수백만 명의 사람들은 약값이 더욱 낮아질 것이다. 여러분의 처방약에 대한 금액 지불은 2,000달러를 초과하지 않도록 제한될 것이다. 이로써 여러분은 더 많은 돈을 주머니에 넣을 수 있다&#8221; 라며 미국 보건인구사회부의 자비에르 베서라(Xavier Becerra) 행정부 장관은 말했다.
&#8220;파트 D 약물 혜택 개선은 물론, 이번 결제 업데이트로 인해 이들 프로그램에 의존하는 메디케어 관리 보험 계획에 대한 결제도 개선되었다. 바이든-해리스 행정부는 미국 국민들의 건강 관리 비용을 계속해서 낮추겠다. 이는 대통령이 한 약속을 지키기 위한 것이다.&#8221;
다른 뉴스들: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38030693/galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress">Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst</a>
UNH, HUM, CVS 주가 움직임: 월요일 시간외 거래에서, <a href="http://pro.benzinga.com">Benzinga Pro</a>(벤징가 프로) 따르면, 미국 헬스케어의 주가는 해당 뉴스로 4.5% 하락했다. 휴매나는 9.6% 하락했으며, CVS 주식은 5.92% 빠졌다.
사진: UnitedHealth의 제공

Comments

UnitedHealth Group

뉴스

에 대한 최신 뉴스 UnitedHealth Group (NYSE:UNH) 주식

월요일, 11월 04, 2024

월요일, 10월 14, 2024

토요일, 9월 21, 2024

월요일, 7월 22, 2024

수요일, 7월 17, 2024

화요일, 7월 16, 2024

화요일, 4월 23, 2024

월요일, 4월 22, 2024

화요일, 4월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌